US Broker Ratings

Amneal Pharmaceuticals, Inc. (AMRX): Investor Outlook Highlights 26.79% Potential Upside

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a prominent player in the healthcare sector focused on specialty and generic drug manufacturing, stands as an intriguing prospect for investors seeking potential growth within..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Navigating a 11.56% Potential Upside in the Biotech Arena

Investors with an appetite for potential growth in the biotech sector should consider Protagonist Therapeutics, Inc. (NASDAQ: PTGX). With a market capitalization of $6.17 billion, this Newark, California-based company is..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A Look at Its 150% Potential Upside

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stands as a beacon of innovation in the biotechnology industry, particularly in the niche of rare and ultra-rare genetic diseases. With a market cap of..

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: Exploring a 28.66% Upside Potential in the Healthcare Robotics Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is carving a niche for itself in the healthcare sector, particularly within the medical devices industry. This San Jose-based company is known for its innovative..

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Uncovering a 37.15% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is making waves in the biotechnology sector, offering investors a tantalizing opportunity with its potential upside of 37.15%. As a commercial-stage biopharmaceutical company, Catalyst focuses..

Warby Parker Inc. (WRBY) Stock Analysis: Eyeing a 13.40% Upside with Strong Buy Ratings

Warby Parker Inc. (WRBY), a notable player in the healthcare sector, is garnering attention with its promising investment outlook. Known for its innovative approach to selling eyewear products, this New..

Concentra Group Holdings Parent (CON): A Promising Investment with 28% Upside Potential

Concentra Group Holdings Parent, Inc. (NASDAQ: CON), a key player in the healthcare sector, is making waves among investors with its strong foothold in the medical care facilities industry. Headquartered..

ImmunityBio, Inc. (IBRX) Stock Analysis: Eyeing an 80% Potential Upside in the Biotech Arena

In the ever-evolving landscape of biotechnology, ImmunityBio, Inc. (NASDAQ: IBRX) stands out with its ambitious innovations in immunotherapy. Based in San Diego, California, ImmunityBio is at the forefront of developing..

Metsera, Inc. (MTSR) Stock Analysis: A Clinical-Stage Biotech with a -19.15% Potential Downside

Metsera, Inc. (MTSR) is a clinical-stage biotechnology company making strides in the healthcare sector, especially in the fight against obesity and related metabolic disorders. Incorporated in 2022 and currently a..

Surgery Partners, Inc. (SGRY) Stock Analysis: Evaluating a 45% Upside Potential in the Healthcare Sector

Surgery Partners, Inc. (NASDAQ: SGRY) stands as a prominent player in the healthcare sector, specifically within the medical care facilities industry. Headquartered in Brentwood, Tennessee, the company boasts a comprehensive..

ICU Medical, Inc. (ICUI) Stock Analysis: Exploring a 36.99% Upside Potential

ICU Medical, Inc. (NASDAQ: ICUI), a key player in the healthcare sector, specializes in the development, manufacturing, and distribution of essential medical instruments and supplies. With a market cap of..

Zai Lab Limited (ZLAB): Analyst Consensus Suggests Over 100% Upside Potential

Zai Lab Limited (NASDAQ: ZLAB), a notable player in the biotechnology sector, is capturing attention with its promising growth potential and strategic collaborations. With a market capitalization of $2.12 billion,..

Arcellx, Inc. (ACLX) Stock Analysis: Strong Pipeline but Challenging Financials

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company specializing in innovative immunotherapies, is currently navigating a complex financial landscape while advancing its promising clinical pipeline. With a market capitalization of $6.7..

Soleno Therapeutics (SLNO) Investor Outlook: Biotech Stock Poised for a Potential 170% Upside

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is capturing investor attention with a standout potential upside of 170.63%, according to recent analyst ratings. This biopharmaceutical company, headquartered in Redwood City, California, is..

Sarepta Therapeutics (SRPT) Stock Analysis: Is There a 21.77% Upside for Biotech Investors?

Sarepta Therapeutics, Inc. (SRPT), a prominent player in the biotechnology sector, is capturing investor attention with its strategic focus on RNA-targeted therapeutics and gene therapy for rare diseases. Headquartered in..

Repligen Corporation (RGEN) Stock Analysis: Uncovering a 55% Potential Upside

Repligen Corporation (NASDAQ: RGEN), a prominent player in the Healthcare sector, has been making waves in the Medical Instruments & Supplies industry. With a market capitalization of $6.76 billion, this..

Integer Holdings Corporation (ITGR) Stock Analysis: Uncovering a 10% Potential Upside in Medical Devices

Integer Holdings Corporation (NYSE: ITGR) stands as a key player in the medical devices sector, offering a diverse portfolio of products and services. With a market capitalization of $2.94 billion,..

iRhythm Holdings, Inc. (IRTC) Stock Analysis: A Deep Dive into a Promising 72% Potential Upside

iRhythm Holdings, Inc. (NASDAQ: IRTC) is making waves in the healthcare sector, specifically within the medical devices industry. Specializing in innovative cardiac monitoring solutions, iRhythm has established itself as a..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing a 9.28% Upside Potential

Bausch + Lomb Corporation (NYSE: BLCO) stands as a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $6.06 billion,..

Krystal Biotech, Inc. (KRYS) Stock Analysis: A Promising 23.47% Potential Upside in Genetic Medicine

Krystal Biotech, Inc. (NASDAQ: KRYS) is swiftly carving out a significant niche in the healthcare sector with its groundbreaking genetic medicines. As a commercial-stage biotechnology company based in the United..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds